Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 3
2011 pubmed 12 citations

Insulin and growth hormone-releasing peptide-6 (GHRP-6) have differential beneficial effects on cell turnover in the pituitary, hypothalamus and cerebellum of streptozotocin (STZ)-induced diabetic rats.

Granado. Miriam M; García-Cáceres. Cristina C; Tuda. María M; Frago. Laura M LM; Chowen. Julie A JA; Argente. Jesús J

Key Findings

  • Insulin alone prevented cell death in the pituitary and restored prolactin and growth‑hormone mRNA levels.
  • GHRP-6 by itself did not reduce diabetes‑induced cell death in the hypothalamus or cerebellum.
  • Combined insulin + GHRP-6 prevented the drop in GFAP (a glial marker) in the hypothalamus and reduced apoptosis in the cerebellum.

Practical Outcomes

  • For biohackers interested in neuro‑protective strategies, the data suggest that GHRP-6 may only be useful when paired with insulin, not on its own. However, insulin is a prescription drug and the study was done in diabetic rats, so direct translation to healthy humans is uncertain. More research is needed before adding GHRP-6 to longevity protocols.

Summary

In diabetic rats, giving insulin helped protect pituitary cells, but didn’t stop brain cell loss. Adding the peptide GHRP-6 to insulin gave extra protection in the hypothalamus and cerebellum, while GHRP-6 alone did nothing. The study shows the two hormones work together in some brain areas, but insulin alone isn’t enough for full protection.

Abstract

Poorly controlled type1 diabetes is associated with hormonal imbalances and increased cell death in different tissues, including the pituitary, hypothalamus and cerebellum. In the pituitary, lactotrophs are the cell population with the greatest increase in cell death, whereas in the hypothalamus and cerebellum astrocytes are most highly affected. Insulin treatment can delay, but does not prevent, diabetic complications. As ghrelin and growth hormone (GH) secretagogues are reported to prevent apoptosis in different tissues, and to modulate glucose homeostasis, a combined hormonal treatment may be beneficial. Hence, we analyzed the effect of insulin and GH-releasing peptide 6 (GHRP-6) on diabetes-induced apoptosis in the pituitary, hypothalamus and cerebellum of diabetic rats. Adult male Wistar rats were made diabetic by streptozotocin injection (65 mg/kg ip) and divided into four groups from diabetes onset: those receiving a daily sc injection of saline (1 ml/kg/day), GHRP-6 (150 μg/kg/day), insulin (1-8U/day) or insulin plus GHRP-6 for 8 weeks. Control non-diabetic rats received saline (1 ml/kg/day). Diabetes increased cell death in the pituitary, hypothalamus and cerebellum (P<0.05). In the pituitary, insulin treatment prevented diabetes-induced apoptosis (P<0.01), as well as the decline in prolactin and GH mRNA levels (P<0.05). In the hypothalamus, neither insulin nor GHRP-6 decreased diabetes-induced cell death. However, the combined treatment of insulin+GHRP-6 prevented the diabetes induced-decrease in glial fibrillary acidic protein (GFAP) levels (P<0.05). In the cerebellum, although insulin treatment increased GFAP levels (P<0.01), only the combined treatment of insulin+ GHRP-6 decreased diabetes-induced apoptosis (P<0.05). In conclusion, insulin and GHRP-6 exert tissue specific effects in STZ-diabetic rats and act synergistically on some processes. Indeed, insulin treatment does not seem to be effective on preventing some of the diabetes-induced alterations in the central nervous system.

Study Information

Provider

pubmed

Year

2011

Date

2011-02-23T00:00:00.000Z

DOI

10.1016/j.mce.2011.02.002

Citations

12

References

79